Press Release June 2018 The phase 1b of our Myasthenia Gravis Therapeutic Vaccine demonstrates an excellent safety profile February 2016 16.02.09 Curavac Plans Ph2 Studies December 2015 Press release_MYASTERIX_December_2015 June 2014 PR_Bio_2014_June
